Michael C. Grant, MD Central MessageThe COVID-19 pandemic provides opportunity to evaluate the role of circulatory support in patients with ARDS. Leveraging the moment will require precise definitions and meticulous study designs. See Article page XXX.

Amid the present pandemic, clinical researchers are once again confronted with the challenge posed by patients with acute respiratory distress syndrome (ARDS). As of this writing, more than 2.6 million people in the United States have been diagnosed and 127,000 have died as a result of severe acute respiratory syndrome coronavirus 2, the virus that causes coronavirus 2019 (COVID-19).[@bib1] Although hospitalization rates are difficult to track, models forecast admissions to potentially crest at about 15,000 per day domestically,[@bib2] with a significant percentage of those patients requiring mechanical ventilation due to ARDS. It is often said that adversity breeds innovation and given both the volume and acuity of the moment, opportunity for advancement in our understanding of the management of this vexing disease is undeniable.

In this context, the letter by Joyce[@bib3] introduces a provocative, if not potentially visionary, approach to the treatment of ARDS. The letter summarizes the experience at the Medical College of Wisconsin, where multidisciplinary teams are utilizing the transcatheter Protek Duo Right Ventricular Assist Device (LivaNova PLC, Houston, Tex) to not only support the right ventricle, which is commonly implicated when hemodynamic instability results, but also as a means to facilitate extubation, avoiding the known harmful effects of mechanical ventilation in this population. The rationale for the approach has merit and early results among 9 consecutive patients are compelling.

The inherent hypothesis of the piece was nonetheless striking in its generality, namely that offloading the right ventricle will mitigate cardiopulmonary compromise. Although this mechanism may contribute to the clinical dilemma,[@bib4] our understanding of COVID-19 is ever-evolving. Some have proposed that the pulmonary effects may be represented by multiple phenotypes that respond differently to hallmark lung-protective ventilation strategies.[@bib5], [@bib6], [@bib7] Furthermore, ARDS has a wide spectrum of presentations and severity.[@bib8] Concomitant neurologic impairment, multiorgan dysfunction, and coagulopathy are wide ranging and unpredictable. When considering the care of COVID-19 patients, teams should guard against the impulse to cast generalizations and assign interventions in broad swaths. Rather, this disease calls for the development of precise definitions and inclusion criteria to properly classify patients and assign therapies.

It is encouraging to read that the team in Wisconsin is preparing to conduct a multicenter prospective trial, and the devil of such study remains in the details. Recall that extracorporeal membrane oxygenation (ECMO) for ARDS---although theoretically ideal as a tool to avoid positive pressure ventilation and ensure lung rest and recovery---remains controversial, in part due to the challenges of conducting appropriate clinical trials. Promising early results suggesting improved mortality with ECMO for ARDS were criticized due to inconsistencies in care among control patients.[@bib9] Unfortunately, a more recent study with improved standardization could not recreate this mortality benefit, potentially the result of high crossover due to the use of ECMO for rescue therapy.[@bib10] Put simply, the management of ARDS is complicated and study of ECMO is messy. Although the solution will almost certainly be the result of splitting rather than lumping, centers with adequate resources and expertise are encouraged to leverage this moment to translate innovative anecdotes into new standards of care.
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